Skip to main content

Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).

Publication ,  Conference
Vlahovic, G; Archer, GE; Lally-Goss, D; Reap, E; Desjardins, A; Peters, KB; Randazzo, D; Healy, P; Herndon, JE; Friedman, AH; Friedman, HS ...
Published in: Journal of Clinical Oncology
May 20, 2015

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15_suppl

Start / End Page

e13030 / e13030

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Vlahovic, G., Archer, G. E., Lally-Goss, D., Reap, E., Desjardins, A., Peters, K. B., … Sampson, J. H. (2015). Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM). In Journal of Clinical Oncology (Vol. 33, pp. e13030–e13030). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2015.33.15_suppl.e13030
Vlahovic, Gordana, Gerald E. Archer, Denise Lally-Goss, Elizabeth Reap, Annick Desjardins, Katherine B. Peters, Dina Randazzo, et al. “Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).” In Journal of Clinical Oncology, 33:e13030–e13030. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e13030.
Vlahovic G, Archer GE, Lally-Goss D, Reap E, Desjardins A, Peters KB, et al. Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. e13030–e13030.
Vlahovic, Gordana, et al. “Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).Journal of Clinical Oncology, vol. 33, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2015, pp. e13030–e13030. Crossref, doi:10.1200/jco.2015.33.15_suppl.e13030.
Vlahovic G, Archer GE, Lally-Goss D, Reap E, Desjardins A, Peters KB, Randazzo D, Healy P, Herndon JE, Friedman AH, Friedman HS, Bigner DD, Sampson JH. Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2015. p. e13030–e13030.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2015

Volume

33

Issue

15_suppl

Start / End Page

e13030 / e13030

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences